Compare TotalEnergies SE (TTE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs Zoetis Inc — how do they compare? TotalEnergies SE trades at $86.42 (market cap $191.82B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: TotalEnergies SE is far larger — about 6.4× Zoetis Inc's market cap, and TotalEnergies SE pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 90 Days and Zoetis Inc for 70 Days on average.
| TTE | ZTS | |
|---|---|---|
Market Cap | $191.82B | $30.20B |
Volume | 3,311,339 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $93.60 | $147.53 |
52-Week Low | $57.39 | $69.09 |
Typical Hold Time | 90 Days | 70 Days |
Enterprise Value | $222.81B | $37.76B |
Dividend Yield | 4.93% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $87.25, up 3.59% today, with a bearish technical signal but strong fundamentals including a low P/E of 10.77 and robust cash flow. Recent earnings beat expectations in Q1 and Q2 2026, while the company announced a $10 billion investment in Argentina and plans for dividend growth through 2030, signaling strategic expansion.
The outlook is positive with analyst consensus at Buy and a $95.33 price target, though risks include declining revenue trends and geopolitical exposure. Upside potential hinges on execution of growth initiatives and energy price stability, while investor sentiment remains supported by shareholder returns.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
